Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar desktop iconMarkt Monitor

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,770   +0,000   (+0,07%) Dagrange 0,769 - 0,793 3.496.790   Gem. (3M) 5M

Estimated peak sales potential in U.S. in HAE of approximately $200 million

58 Posts
Pagina: 1 2 3 »» | Laatste | Omlaag ↓
  1. sniper22 11 januari 2011 23:21
    Granted Orphan Drug and Fast Track Status in U.S. for treatment of acute attacks of HAE
    •BLA submitted in U.S. in late December 2010
    •European Medicines Agency approved Rhucin (Ruconest™ in Europe) in October 2010 for treatment of acute attacks of HAE (Swedish Orphan Biovitrum has E.U. rights)
    •Rhucin may also have potential in other indications
    –Antibody-mediated rejection following solid organ transplantation
    –Delayed graft function following solid organ transplantation
    •Two U.S. patents expire in 2020 and 2022
    –Expect to have 12 years of data exclusivity for biologic product upon FDA approval
    •Estimated peak sales potential in U.S. in HAE of approximately $200 million
58 Posts
Pagina: 1 2 3 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.